FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer
September 08 2020 - 7:00AM
FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Percy
Carter, MBA, PhD, to the newly-created position of Chief Scientific
Officer, where he will lead FibroGen’s research efforts, leveraging
more than 20 years of global biopharmaceutical leadership and
experience.
“Great science and innovation are the backbone of FibroGen and
what enable us to develop transformational medicines for patients.
With Percy’s leadership, we will continue our legacy of biological
breakthroughs and advancing first-in-class therapeutics,” said
Enrique Conterno, Chief Executive Officer, FibroGen. “Percy’s
expertise and experience make him the ideal person to lead
FibroGen’s scientific agenda. I look forward to his leadership
impact on advancing our unique position in both hypoxia-inducible
factor and connective tissue growth factor biology to expand our
pipeline of novel drug candidates.”
Dr. Carter most recently served as Global Head of Discovery
Sciences at Janssen (Pharmaceutical Companies of Johnson &
Johnson) where he led a global organization of over 700 employees
comprising several key functions, including: Computational
Sciences; Discovery Chemistry; Drug Metabolism &
Pharmacokinetics; Lead Discovery; and Core Business Services. Percy
worked in collaboration with therapeutic area discovery scientists
and other stakeholders to define and operationalize innovative
strategies for the successful identification and optimization of
novel small molecule, peptide, and RNA-based drug candidates.
Prior to his role with Janssen, Percy was Senior Vice President
and Head of Discovery for Bristol-Myers Squibb (BMS). For almost
two decades at BMS, he held roles of increasing responsibility in
drug discovery, covering all therapeutic areas, drug platforms and
stages of discovery. Percy began his career as a Senior Research
Scientist in Chemical and Physical Sciences at DuPont
Pharmaceuticals, and joined BMS when the company acquired DuPont
Pharmaceuticals in 2001. During his combined time at BMS and
DuPont, he collaborated with a wide range of colleagues to help
build the immunoscience pipeline. In 2013, after moving into a
cross-therapeutic area role, Percy worked on advancing the overall
portfolio, driving innovation in supporting technologies,
non-traditional modalities, and novel external partnerships. Dr.
Carter also led the BMS/Syngene R&D collaboration at the BBRC
in Bangalore, India for two years across all aspects of
discovery.
Percy is an inventor or co-inventor on more than 28 U.S. patents
and has authored or co-authored more than 85 peer-reviewed
publications. He received his bachelor’s degree in Organic
Chemistry from Dartmouth College, his PhD in Chemistry &
Chemical Biology from Harvard University, and completed a
post-doctoral fellowship at Harvard Medical School and
Massachusetts General Hospital. In 2014, he received his MBA from
the Massachusetts Institute of Technology.
“I’ve been impressed by the innovation at FibroGen. I’m excited
to take on this unique opportunity at a company with expansive HIF
and CTGF expertise,” said Dr. Carter. “I look forward to working
with the research organization to advance the next wave of
medicines.”
About FibroGenFibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing and
commercializing a pipeline of first-in-class therapeutics. The
company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology to
advance innovative medicines to treat unmet needs. The Company is
currently developing and commercializing roxadustat, an oral small
molecule inhibitor of HIF prolyl hydroxylase activity, for anemia
associated with chronic kidney disease (CKD). Roxadustat is also in
clinical development for anemia associated with myelodysplastic
syndromes (MDS) and for chemotherapy-induced anemia (CIA).
Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical
development for the treatment of idiopathic pulmonary fibrosis
(IPF), locally advanced unresectable pancreatic cancer (LAPC),
Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For
more information, please visit www.fibrogen.com.
Forward-Looking StatementsThis release contains
forward-looking statements regarding our strategy, future plans and
prospects, including statements regarding the development and
commercialization of the company’s product candidates. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as “may,” “will”, “should,” “on
track,” “could,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the continued progress and timing of our various
programs, including the enrollment and results from ongoing and
potential future clinical trials, and other matters that are
described in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2019 and our Quarterly Report on Form 10-Q for
quarter ended June 30, 2020 filed with the Securities and Exchange
Commission (SEC), including the risk factors set forth therein.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
Contact:FibroGen, Inc.
Media Inquiries:Sara
Iacovino1.703.474.4452sara.iacovino@gcihealth.com
Investors:Michael Tung, MDCorporate Strategy / Investor
Relations 1.415.978.1434mtung@fibrogen.com
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024